This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction

PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction

Format

Webcast

Time to Complete

45 minutes

Released

November 19, 2019

Expires

November 19, 2020
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 Credit(s)TM
0.75 / ABIM MOC Point

An important note about ABIM MOC Part II points
Successful completion of this CME activity enables eligible participants to earn up to 0.75 ABIM-Part II Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. To claim MOC points, follow these easy steps:

Step 1: Complete all 3 questions under the "ABIM Part 2 Credit Questions" section, located at the bottom of the course evaluation form. This includes 1) attesting that our partner may submit your credits to ABIM and that you are ABIM board certified, 2) providing your ABIM #, and 3) providing your date of birth (MM/DD).

Step 2: Our partner, Horizon CME, will send your MOC points to your ABIM account within 6-8 weeks.

Accredited Provider



Provided by Horizon CME

Commercial Supporter

This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.

Program Description

Management of patients with elevated cardiovascular risk and hypercholesterolemia requires an understanding of evidence-based lipid targets and effective lipid-lowering therapy. Clinicians who manage these patients are challenged by evolving blood cholesterol guidelines, treatment targets, new lipid-lowering therapies, and the clinical considerations to lower cardiovascular risk and achieve optimal patient outcomes. This interactive, personalized webcast educates learners on the current cardiovascular outcomes data for PCSK9 inhibitors in patients at increased risk for CV events, how to integrate non-statin lipid-lowering therapies into lipid management plans for high CV risk patients requiring additional LDL-C reduction, and strategies for improving access to PCSK9 inhibitors for high CV risk patients not achieving LDL-C goals.

Intended Audience

Lipid Specialists, Cardiologists, Endocrinologists, Primary Care Providers (MDs/DOs), nurse practitioners (NPs), physician assistants (PAs), other healthcare providers who practice in a primary care setting.

Educational Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Assess current cardiovascular outcomes data for PCSK9 inhibitors in patients at increased risk for CV events
  • Integrate PCSK9 inhibitors in the management of real-world patients at high CV risk requiring additional LDL-C reduction
  • Formulate strategies to improve patient access to PCSK9 inhibitors for those who require further CV risk reduction

Conflict of Interest Disclosure Policy

Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members’ relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

Faculty

Douglas S. Jacoby, MD, FACC, FNLA
Medical Director
Penn Medicine Center for Preventive Cardiology and Lipid Management
Associate Professor of Clinical Medicine
University of Pennsylvania

Dr. Jacoby has served on a Lipid Expert Advisory Panel for Regeneron and conducted education on advanced lipid testing for Quest.

Co-Content Chairs
James Underberg MD, MS, FACPM, FACP, FASH, FNLA
has served on a Speakers Bureau for Amgen, Sanofi, Regeneron, Amarin, Akacea and Alexion. He has served as a Consultant for Amgen and Ambry and performed contracted research for Aegerion.

P. Barton Duell, MD has served as a Consultant for Akcea, Astra Zeneca, Regeneron, Regenxbio, Esperion, and Retrophin. Institutional Grants were received from Regeneron, Regenxbio, Esperion and Retrophin.

Accredited Provider Disclosures

Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclose no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months.

Publishing Staff Disclosures

David T Lee, DO, FACC provided external peer review of this activity.David Lee has not had any relevant financial relationships within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Horizon CME designates this activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part II Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the post-test (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately.

For questions regarding CME credit, please contact Marsha Jack at Horizon CME (503) 659-5558.

Add to Queue